On this page
Overview
Product & regulatory status
FDA-approved prescription drug for specified breast-cancer treatment and risk-reduction indications; many male hormone uses are off label.
Tissue-dependent receptor effects
Tamoxifen opposes estrogen effects in breast tissue while having different effects in other tissues, helping explain its benefits and risks. [1]
What the evidence shows
Cancer-risk reduction has a defined population
In NSABP P-1, women at increased breast-cancer risk had fewer invasive cancers with tamoxifen than placebo after a median 4.2 years. The label reports a 44% relative reduction, without an overall mortality difference at that analysis. [1]
Gynecomastia evidence is much smaller
A 1986 placebo-controlled crossover study included ten patients. Seven had partial breast-size reduction and four with pain reported relief. This small, short study does not establish a universal treatment or long-term safety estimate. [2]
What remains unknown
Benefit-risk depends strongly on the indication and baseline risk. Evidence for painful gynecomastia does not establish a general-purpose hormone-recovery strategy.
Safety
Serious harms
Labeling identifies thromboembolism, stroke, endometrial cancer and cataracts among important risks. Their relevance and absolute frequency vary with the treated population. [1]
Absence of events in ten people is not reassurance
The small gynecomastia trial reported no toxicity, but could not reliably detect uncommon or delayed adverse effects. [2]
Prescription product
The cited evidence concerns oral tamoxifen citrate. Combination supplements or research preparations do not inherit that product evidence. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does it lower all estrogen production?
No. It modulates estrogen-receptor effects; it is pharmacologically different from an aromatase inhibitor.
What should a new breast symptom prompt?
A clinical assessment of its cause before assuming it represents a hormone imbalance suitable for tamoxifen.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Tamoxifen citrate prescribing informationUS label; breast-cancer indications, NSABP P-1 outcomes and major adverse effects.
- Parker et al.: tamoxifen for gynecomastiaMetabolism, 1986; placebo-controlled crossover trial in ten patients.
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.